Euroopa Liit - eesti - EMA (European Medicines Agency)

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomüoom - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mylan pharmaceuticals limited - fulvestrant - rinnanäärmed - endokriinset ravi - fulvestrant on näidustatud ravi östrogeeni retseptor positiivne, lokaalselt kaugelearenenud või metastaatilise rinnavähi postmenopausis naised:ei ole varem ravitud endokriinse ravi, orwith haiguse retsidiivi või pärast abiaine anti-östrogeeni ravi või haiguse progresseerumise kohta ravi antiestrogen.

Eesti - eesti - Ravimiamet

baxter holding b.v. - ondansetroon - süstelahus - 2mg 1ml 2ml 25tk; 2mg 1ml 2ml 5tk; 2mg 1ml 4ml 25tk; 2mg 1ml 4ml 5tk

Eesti - eesti - Ravimiamet

stada arzneimittel ag - lidokaiin+kummeliekstrakt - suuõõnegeel - 20mg+185mg 1g 10g 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - losartaan - õhukese polümeerikattega tablett - 25mg 30tk; 25mg 56tk; 25mg 50tk; 25mg 14tk; 25mg 15tk; 25mg 98tk; 25mg 20tk; 25mg 84tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - losartaan - õhukese polümeerikattega tablett - 12,5mg 250tk; 12,5mg 21tk; 12,5mg 84tk; 12,5mg 50tk; 12,5mg 20tk; 12,5mg 7tk; 12,5mg 15tk; 12,5mg 98tk; 12,5mg 112tk; 12,5mg 100tk; 12,5mg 14tk; 12,5mg 10tk; 12,5mg 90tk

Eesti - eesti - Ravimiamet

laboratorios hipra s.a. - koktsiidide vaktsiin - suukaudne suspensioon - 1annus 5000annus 1pudel; 1annus 1000annus 1pudel; 1annus 5000annus 5pudel; 1annus 1000annus 10pudel

Eesti - eesti - Ravimiamet

vitabalans oy - oksükodoon - õhukese polümeerikattega tablett - 10mg 100tk; 10mg 30tk

Eesti - eesti - Ravimiamet

vitabalans oy - oksükodoon - õhukese polümeerikattega tablett - 5mg 100tk